查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999376

肿瘤NGS市场：2026-2032年全球市场预测（按产品类型、癌症类型、技术、检体阶段、应用和最终用户划分）

Oncology NGS Market by Product Type, Cancer Type, Technology, Sample Type, Workflow Stage, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肿瘤学领域的次世代定序(NGS) 市值将达到 40.1 亿美元，到 2026 年将成长至 45.8 亿美元，到 2032 年将达到 108.5 亿美元，复合年增长率为 15.27%。

主要市场统计数据
基准年 2025 40.1亿美元
预计年份：2026年 45.8亿美元
预测年份 2032 108.5亿美元
复合年增长率 (%) 15.27%

全面概述临床定序创新、监管进步和营运架构如何融合，从而重新定义肿瘤学的决策。

次世代定序(NGS) 已从一项实验性技术发展成为肿瘤学研究、诊断和治疗方法开发的核心支柱。高通量定序仪的引入、日益完善的生物资讯流程以及检验的临床检测方法，使得分子谱分析能够辅助诊断、预测治疗反应并监测微量残存疾病。随着技术的融合，检查室和临床团队正在将定序应用于持续的临床实践中，从靶向基因panel分析到全面的EXOME和转录组分析，从而拓展了从患者检体中获取可操作资讯的范围。

定序、资讯学和多组体学整合的技术进步如何重塑肿瘤学的诊断工作流程和临床决策流程。

肿瘤定序领域正经历一场变革，其驱动力来自于技术突破、数据整合以及不断演进的临床范式。短读长定序平台持续优化成本和通量，而长读长定序和单分子定序方法则推进了对以往难以分析的结构变异和复杂基因组区域的表征。同时，检测设计也从广泛的探索性检测转向以临床为中心的设计，优先关注可操作的突变和预测性生物标记物，从而能够快速地将结果反馈到治疗方法的选择中。

为因应 2025 年关税造成的供应链中断，制定营运应对措施和筹资策略，并提高总到岸成本的透明度。

政策变革和贸易措施将对整个诊断生态系统的供应链、成本结构和筹资策略产生重大影响。 2025 年美国关税措施为依赖全球生产系统和复杂组件采购的检查室、试剂生产商和设备供应商带来了新的挑战。为了因应这些变化，企业领导者正在寻求供应商多元化，重新审视库存策略，并调整物流计划，以降低跨境成本波动和潜在交货延迟带来的风险。

详细的細項分析揭示了每种产品类型、癌症类型、应用和最终用户的不同要求，从而影响检测开发和商业化的方法。

细分市场分析揭示了不同产品类型、癌症类型、应用领域和最终用户所面临的细微需求和机会。就产品类型而言，平台需要为分散式临床检查室的桌上型定序仪和支援大规模集中式操作的高通量定序仪进行资本规划。试剂和耗材包括流动池、样品製备盒和定序盒，每种产品的保存期限和低温运输需求各不相同。服务包括数据分析和检体製备服务，这些服务需要根据处理量和监管要求进行规模化调整。

区域趋势和监管差异影响定序能力、报销模式和基础设施投资对全球临床部署的影响。

地理趋势影响法律规范、报销环境和营运模式，从而形成不同的区域优先事项，进而影响技术应用和投资。在美洲，完善的报销机制、成熟的参考检查室网路和活跃的临床试验活动正在推动临床应用，支援集中式高通量定序和分散式诊断检测。该地区支付方、医疗服务提供者和创新者之间的持续互动，加速了实证医学证据的产生，同时也提高了人们对临床效用和疗效的期望。

竞争性创新、策略伙伴关係和能力整合如何推动肿瘤定序平台、试剂和服务供应商之间的差异化。

企业间的竞争与合作动态正在塑造整个肿瘤定序系统的创新路径与服务交付模式。成熟的平台供应商持续投资于仪器性能、通量优化和整合软体，以降低临床应用门槛。同时，专业的试剂和耗材公司则专注于供应链韧性、检测稳健性和跨多种仪器类型的兼容性，以适应不同的检查室环境。服务供应商则透过提供检验的生物资讯解决方案、承包样本到报告工作流程以及临床认证的检查室能力来减轻医疗机构的负担，从而实现差异化竞争优势。

制定可操作的策略重点，透过协调平台模组化、生物资讯检验、供应链弹性和相关人员合作来加速临床部署。

行业领导者必须将技术潜力转化为营运可行且具有临床意义的解决方案，以维持市场地位并加速造福患者。首先，投资于平台相容性和试剂互通性可以降低客户锁定风险，并增强应对供应链中断的能力。优先采用模组化系统结构和开放资料格式，使企业能够在各种不同的检查室环境中实现更广泛的部署。

采用严谨的混合方法，结合对关键相关人员的访谈、文献整合、案例研究和检验，确保获得稳健透明的见解。

本报告透过整合多面向证据，确保了分析的稳健性和观点。主要研究包括对实验室负责人、临床基因组学经理、采购负责人和行业高管进行结构化访谈，以了解实际操作情况、检验要求和采购标准。此外，还系统性地回顾了同行评审文献、临床指南、监管申报文件和公开的技术文檔，并基于已记录的性能和临床有效性进行技术评估。

技术成熟度、证据产生和供应链韧性如何结合起来，决定了肿瘤定序常规临床应用的路径。

总之，肿瘤特异性定序正处于关键时期，技术成熟度、数据整合和政策趋势共同影响其短期发展轨迹。定序化学製程和仪器设计的进步不断拓展分析能力，而资讯科学和结果解读的改进则提升了其临床意义。同时，与关税和区域监管差异相关的供应链问题，也要求进行周密的营运规划，以确保服务可靠运作。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肿瘤NGS市场：依产品类型划分

  • 装置
  • 试剂和耗材
    • 样品製备工具包
    • 定序试剂
    • 靶向序列捕获盒
  • 服务
    • 生物资讯学和数据分析服务
    • 临床报告与解释服务

第九章：按癌症类型分類的肿瘤NGS市场

  • 固体癌
    • 乳癌
    • 肺癌
    • 结肠癌
    • 摄护腺癌
    • 卵巢癌
    • 恶性黑色素瘤
  • 骨髓恶性肿瘤
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤

第十章：肿瘤NGS市场：依技术划分

  • 全基因组定序
  • 全EXOME定序
  • 标靶定序和重定序

第十一章：检体类型分類的肿瘤NGS市场

  • 组织样本
    • 福马林固定石蜡包埋组织
    • 新鲜冷冻组织
  • 液态生物检体样本
    • 电浆
    • 血清
    • 循环性肿瘤细胞

第十二章：肿瘤NGS市场各阶段工作流程

  • 在序列之前
  • 顺序
  • 数据分析

第十三章 肿瘤NGS市场：依应用领域划分

  • 临床诊断
    • 固态肿瘤分析
    • 骨髓恶性肿瘤的分析
    • 生殖系癌易感性检测
    • 微量残存疾病的监测
    • 伴随诊断
  • 调查
    • 肿瘤生物标记的发现
    • 肿瘤异质性研究
    • 抗性机制研究
  • 药物发现
  • 液态生物检体
    • 癌症早期发现
    • 治疗反应监测
    • 復发监测

第十四章 肿瘤NGS市场：依最终用户划分

  • 学术和研究机构
  • 医院和癌症中心
    • 肿瘤学
    • 病理检查室
  • 临床诊断检查室
  • 製药和生物技术公司
  • 合约研究机构

第十五章 肿瘤NGS市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 肿瘤NGS市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 肿瘤NGS市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国肿瘤NGS市场

第十九章：中国肿瘤NGS市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • Burning Rock Dx
  • Creative Biogene
  • DH Life Sciences, LLC
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Genecast Group Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Myriad Genetics, Inc.
  • Oxford Nanopore Technologies plc.
  • Pacific Biosciences of California, Inc.
  • PerkinElmer Inc.
  • Personalis, Inc.
  • Promega Corporation
  • Qiagen NV
  • seqWell
  • SOPHiA GENETICS.
  • Takara Bio Inc.
  • Tecan Trading AG
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience Corporation
Product Code: MRR-3A2E844FECAB

The Oncology NGS Market was valued at USD 4.01 billion in 2025 and is projected to grow to USD 4.58 billion in 2026, with a CAGR of 15.27%, reaching USD 10.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.01 billion
Estimated Year [2026] USD 4.58 billion
Forecast Year [2032] USD 10.85 billion
CAGR (%) 15.27%

A comprehensive orientation to how clinical sequencing innovations, regulatory evolution, and operational readiness are converging to redefine oncology decision making

Next-generation sequencing (NGS) has moved from an experimental capability to a core pillar of oncology research, diagnostics, and therapeutic development. The introduction of high-throughput instruments, increasingly robust bioinformatics pipelines, and validated clinical assays has enabled molecular profiling to inform diagnosis, predict therapeutic response, and monitor minimal residual disease. As technologies converge, laboratories and clinical teams are adopting sequencing across a continuum that spans targeted gene panels to comprehensive exome and transcriptome analyses, thereby expanding the scope of actionable insights derived from patient samples.

Alongside technological maturation, regulatory pathways and reimbursement conversations have become more sophisticated, prompting closer alignment between assay validation and clinical utility evidence generation. Consequently, stakeholders are investing in operational workflows, quality management systems, and data governance to ensure analytic performance translates into reproducible clinical value. This environment is creating a virtuous cycle: improved assay reliability and interpretive frameworks drive clinical adoption, which in turn generates real-world evidence that supports broader integration of NGS into standards of care.

Given the rapidly evolving science and shifting healthcare incentives, organizations must balance near-term operational readiness with strategic investments in platform flexibility, reagent supply resilience, and scalable bioinformatics. The following sections outline transformative shifts, policy impacts, segmentation insights, regional dynamics, competitive considerations, pragmatic recommendations, and the methodological rigor underpinning the analysis.

How technological advances in sequencing, informatics, and multiomic integration are reshaping diagnostic workflows and clinical decision pathways in oncology

The oncology sequencing landscape is undergoing transformative shifts driven by technological breakthroughs, data integration, and evolving clinical paradigms. Short-read platforms have continued to optimize cost and throughput, while long-read and single-molecule approaches have advanced the characterization of structural variants and complex genomic regions that were previously refractory to analysis. Concurrently, assay design has shifted from broad, exploratory panels toward clinically focused content that prioritizes actionable variants and predictive biomarkers, enabling more rapid translation into therapeutic choices.

Informatics has emerged as a central differentiator, with cloud-native pipelines, containerized workflows, and machine learning-assisted variant interpretation improving turnaround times and interpretive consistency. These capabilities are increasingly coupled with standardized reporting frameworks that enhance cross-institutional comparability. At the same time, decentralization trends are accelerating: point-of-care and near-patient testing strategies are being piloted, complementing centralized high-throughput operations to meet diverse clinical needs and reduce time-to-result.

Finally, integration of multiomic data-including RNA sequencing and epigenetic signatures-with clinical and imaging datasets is catalyzing new biomarker discovery and refined risk stratification. As a result, laboratories and vendors are shifting resources toward modular solutions that support hybrid workflows, ensuring that investments remain relevant as diagnostic paradigms continue to evolve.

Operational responses and procurement strategies adapted to tariff-driven supply chain disruptions and increased total landed cost transparency in 2025

Policy changes and trade measures can materially affect supply chains, cost structures, and procurement strategies across the diagnostics ecosystem. Tariff actions in the United States in 2025 have introduced additional considerations for laboratories, reagent manufacturers, and instrument suppliers that rely on globalized production and complex component sourcing. These shifts have prompted operational leaders to reassess supplier diversification, inventory policies, and logistics planning to mitigate exposure to cross-border cost variability and potential delivery delays.

In response, many organizations have accelerated qualification of alternative suppliers and adjusted stocking strategies to maintain uninterrupted services. Procurement teams are increasingly specifying supplier redundancy and localized support as part of contracting criteria, while product developers are evaluating the feasibility of regionalized manufacturing or assembly to reduce tariff-related impacts. At the same time, contract negotiations and service-level agreements are being revisited to incorporate contingency clauses that address tariff volatility and customs-related disruptions.

Importantly, stakeholders are also prioritizing transparency in total landed cost calculations and scenario planning to understand how policy dynamics could influence capital procurement and recurring reagent expenditures. Through these combined responses, operators aim to preserve clinical continuity while maintaining financial predictability in an environment where trade policy represents an elevated operational risk.

Detailed segmentation insights revealing differentiated product, cancer-type, application, and end-user imperatives that shape assay development and commercialization approaches

Segment-level analysis reveals nuanced requirements and opportunity areas that vary by product type, cancer type, application, and end user. When examined through product type, platforms require capital planning for benchtop sequencers that serve decentralized clinical labs as well as high-throughput sequencers that underpin large centralized operations; reagents and consumables span flow cells, library preparation kits, and sequencing kits with distinct shelf-life and cold-chain demands; and services encompass data analysis services and sample preparation services that must scale with volume and regulatory expectations.

When viewed by cancer type, the diagnostic and therapeutic imperatives differ: breast cancer workflows emphasize hormone receptor-related signatures and copy-number analyses, colorectal cancer places a premium on microsatellite instability and tumor mutational burden assessments, hematological malignancies rely on fusion detection and clonality profiling, and lung cancer requires sensitive detection of low-frequency driver mutations. Each cancer type drives differentiated assay design, validation metrics, and clinical reporting priorities.

By application, gene panels deliver focused actionable insights and are widely used for targeted therapy selection, RNA sequencing provides expression and fusion detection that enhance variant interpretation and resistance mechanism elucidation, and whole exome sequencing supports broader discovery applications, germline-somatic differentiation, and complex biomarker development. From the perspective of end users, academic research institutes prioritize flexibility and exploratory capability; diagnostic laboratories focus on throughput, reproducibility, and regulatory compliance; hospitals integrate sequencing into clinical pathways and require operational resilience; and pharma and biotech companies leverage sequencing for trial enrollment, companion diagnostic development, and translational research. These intersecting segmentation axes inform product positioning, validation roadmaps, and commercialization strategies.

Regional dynamics and regulatory diversity shaping how sequencing capabilities, reimbursement models, and infrastructure investments influence clinical adoption globally

Geographic dynamics influence regulatory frameworks, reimbursement environments, and operational models, yielding distinct regional priorities that shape uptake and investment. In the Americas, clinical adoption is driven by established reimbursement pathways, a mature network of reference laboratories, and active clinical trial activity, which together support both centralized high-throughput sequencing and distributed diagnostic testing. Continuous interaction between payers, providers, and innovators in this region accelerates evidence generation while raising expectations for clinical validity and utility.

In Europe, Middle East & Africa, regulatory heterogeneity combined with divergent healthcare funding models fosters a mixed landscape in which national-level policy decisions and collaborative regional initiatives determine the pace of integration. Laboratories must navigate varied certification regimes and align assays with country-specific clinical guidelines. Meanwhile, stakeholders across this region emphasize harmonized data standards and interoperability to enable cross-border research and pooled evidence generation.

In the Asia-Pacific region, rapid investments in sequencing infrastructure, growing domestic reagent manufacturing, and strong clinical trial pipelines are driving significant momentum. Diverse healthcare systems and varying levels of centralized laboratory capacity create opportunities for both scalable high-throughput facilities and adaptable benchtop solutions. Across all regions, cross-border collaborations, local validation studies, and attention to regulatory alignment remain essential to accelerate the translation of sequencing into routine oncology care.

How competitive innovation, strategic partnerships, and capability consolidation are driving differentiation across platforms, reagents, and service providers in oncology sequencing

Competitive and collaborative dynamics among companies are shaping innovation pathways and service delivery across the oncology sequencing ecosystem. Established platform providers continue to invest in instrument performance, throughput optimization, and integrated software to lower barriers to clinical adoption. Meanwhile, reagent and consumable specialists are focusing on supply-chain resilience, assay robustness, and compatibility across multiple instrument types to appeal to diverse laboratory footprints. Service providers are differentiating through validated bioinformatics offerings, turn-key sample-to-report workflows, and clinically accredited laboratory capabilities that reduce burden for healthcare providers.

Strategic partnerships between technology vendors, clinical laboratories, and pharmaceutical developers are increasingly common, as co-development agreements accelerate companion diagnostic programs and enable more efficient patient stratification in therapeutic trials. Emerging companies are concentrating on niche areas such as ultra-sensitive liquid biopsy assays, multiomic panels, and AI-enhanced interpretation platforms that address unmet clinical needs. In parallel, investment activity and targeted acquisitions continue to consolidate capabilities where scale and regulatory experience deliver competitive advantage.

Across these dynamics, successful organizations are prioritizing reproducibility, regulatory readiness, and customer support infrastructure that spans training, assay validation, and post-market surveillance. These capabilities underpin trust among clinicians and payers and differentiate suppliers in a market where clinical evidence and operational reliability are decisive.

Actionable strategic priorities that align platform modularity, bioinformatics validation, supply resilience, and stakeholder engagement to accelerate clinical adoption

Industry leaders must translate technological promise into operationally viable, clinically meaningful solutions to retain market relevance and accelerate patient impact. First, investing in platform compatibility and reagent interoperability reduces customer lock-in risk and enhances resilience against supply-chain disruptions. By prioritizing modular system architectures and open-data formats, organizations can enable broader adoption across heterogeneous laboratory environments.

Second, strengthening bioinformatics and interpretation capabilities is essential. This means investing in validated pipelines, standardized variant curation frameworks, and clinically focused reporting templates that reduce time-to-action for clinicians. Equally important is the development of clinician-facing educational programs and interpretation support that contextualize genomic findings within treatment pathways.

Third, leaders should formalize supplier diversification and regionalization strategies to mitigate tariff exposure and logistics risk. This includes qualifying alternative vendors, building strategic inventory buffers, and exploring regional manufacturing or assembly where feasible. Additionally, proactive engagement with regulatory bodies and payer stakeholders will ensure that evidence generation aligns with evolving expectations for clinical utility and reimbursement.

Finally, adopting a customer-centric commercialization approach that bundles technical support, validation services, and evidence-generation partnerships will accelerate adoption. By aligning product roadmaps with clinical workflows and trial requirements, organizations can deliver solutions that are not only scientifically advanced but also operationally and economically accessible.

A rigorous mixed-methods approach combining primary stakeholder interviews, literature synthesis, case studies, and triangulation to ensure robust and transparent insights

The analysis underpinning this report combines multiple evidence streams to ensure a robust and defensible perspective. Primary research included structured consultations with laboratory directors, clinical genomics leads, procurement officers, and industry executives to capture operational realities, validation requirements, and procurement criteria. These inputs were complemented by a systematic review of peer-reviewed literature, clinical guidelines, regulatory filings, and publicly available technical documentation to ground technology assessments in documented performance and clinical relevance.

Quantitative and qualitative triangulation methods were applied to reconcile disparate data sources, while case-study analyses of representative laboratory implementations provided practical insights into workflow optimization, turnaround-time drivers, and quality-control practices. The assessment of supply-chain and tariff impacts incorporated customs rulings, trade policy analyses, and logistics expert interviews to evaluate potential operational responses and mitigation strategies.

To ensure transparency, the methodology documents data sources, interview protocols, inclusion criteria, and key assumptions, and highlights limitations such as variability in regional regulatory timelines and heterogeneity in laboratory accreditation standards. Wherever applicable, data were validated through follow-up interviews with subject-matter experts and cross-checked against technical specifications and published clinical performance metrics.

Synthesis of how technology maturation, evidence generation, and supply-chain resilience collectively determine the path to routine clinical integration of oncology sequencing

In sum, oncology-focused sequencing is at an inflection point where technical maturity, data integration, and policy dynamics collectively determine near-term trajectories. Advances in sequencing chemistry and instrument design are expanding analytic capabilities, while improvements in informatics and interpretation are enhancing clinical relevance. At the same time, tariff-related supply-chain considerations and regional regulatory heterogeneity require deliberate operational planning to sustain reliable service delivery.

Organizations that succeed will be those that couple technological leadership with disciplined operational strategies: investing in interoperable platforms and validated reagents, strengthening interpretation pipelines, securing diversified supply chains, and engaging regulators and payers early in evidence development. For clinical laboratories and healthcare providers, the imperative is to embed sequencing within reproducible workflows and quality systems that deliver timely, actionable reports. For developers and investors, the priority is to align product development with clinical utility and regulatory readiness to ensure uptake.

Ultimately, the integration of sequencing into routine oncology care will be incremental and evidence-driven. By focusing on reproducibility, clinical impact, and supply resilience, stakeholders can accelerate adoption in ways that translate scientific progress into measurable patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncology NGS Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Consumables
    • 8.2.1. Library Preparation Kits
    • 8.2.2. Sequencing Reagents
    • 8.2.3. Target Enrichment Kits
  • 8.3. Services
    • 8.3.1. Bioinformatics & Data Analysis Services
    • 8.3.2. Clinical Reporting & Interpretation Services

9. Oncology NGS Market, by Cancer Type

  • 9.1. Solid Tumors
    • 9.1.1. Breast Cancer
    • 9.1.2. Lung Cancer
    • 9.1.3. Colorectal Cancer
    • 9.1.4. Prostate Cancer
    • 9.1.5. Ovarian Cancer
    • 9.1.6. Melanoma
  • 9.2. Hematologic Malignancies
    • 9.2.1. Leukemia
    • 9.2.2. Lymphoma
    • 9.2.3. Myeloma

10. Oncology NGS Market, by Technology

  • 10.1. Whole Genome Sequencing
  • 10.2. Whole Exome Sequencing
  • 10.3. Targeted Sequencing & Resequencing

11. Oncology NGS Market, by Sample Type

  • 11.1. Tissue Samples
    • 11.1.1. Formalin-Fixed Paraffin-Embedded Tissue
    • 11.1.2. Fresh Frozen Tissue
  • 11.2. Liquid Biopsy Samples
    • 11.2.1. Plasma
    • 11.2.2. Serum
    • 11.2.3. Circulating Tumor Cells

12. Oncology NGS Market, by Workflow Stage

  • 12.1. Pre-Sequencing
  • 12.2. Sequencing
  • 12.3. Data Analysis

13. Oncology NGS Market, by Application

  • 13.1. Clinical Diagnostics
    • 13.1.1. Solid Tumor Profiling
    • 13.1.2. Hematologic Malignancy Profiling
    • 13.1.3. Germline Cancer Predisposition Testing
    • 13.1.4. Minimal Residual Disease Monitoring
    • 13.1.5. Companion Diagnostics
  • 13.2. Research
    • 13.2.1. Oncology Biomarker Discovery
    • 13.2.2. Tumor Heterogeneity Studies
    • 13.2.3. Resistance Mechanism Studies
  • 13.3. Drug Development
  • 13.4. Liquid Biopsy
    • 13.4.1. Early Cancer Detection
    • 13.4.2. Treatment Response Monitoring
    • 13.4.3. Recurrence Surveillance

14. Oncology NGS Market, by End User

  • 14.1. Academic & Research Institutions
  • 14.2. Hospitals & Cancer Centers
    • 14.2.1. Oncology Departments
    • 14.2.2. Pathology Laboratories
  • 14.3. Clinical Diagnostic Laboratories
  • 14.4. Pharmaceutical & Biotechnology Companies
  • 14.5. Contract Research Organizations

15. Oncology NGS Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Oncology NGS Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Oncology NGS Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Oncology NGS Market

19. China Oncology NGS Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Agilent Technologies, Inc.
  • 20.6. BGI Group
  • 20.7. Bio-Rad Laboratories, Inc.
  • 20.8. Burning Rock Dx
  • 20.9. Creative Biogene
  • 20.10. DH Life Sciences, LLC
  • 20.11. Eurofins Scientific S.E.
  • 20.12. Exact Sciences Corporation
  • 20.13. F. Hoffmann-La Roche Ltd
  • 20.14. Genecast Group Inc.
  • 20.15. Guardant Health, Inc.
  • 20.16. Hologic, Inc.
  • 20.17. Illumina, Inc.
  • 20.18. Invivoscribe, Inc.
  • 20.19. Myriad Genetics, Inc.
  • 20.20. Oxford Nanopore Technologies plc.
  • 20.21. Pacific Biosciences of California, Inc.
  • 20.22. PerkinElmer Inc.
  • 20.23. Personalis, Inc.
  • 20.24. Promega Corporation
  • 20.25. Qiagen N.V.
  • 20.26. seqWell
  • 20.27. SOPHiA GENETICS.
  • 20.28. Takara Bio Inc.
  • 20.29. Tecan Trading AG
  • 20.30. Thermo Fisher Scientific, Inc.
  • 20.31. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLOGY NGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLOGY NGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLOGY NGS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY NGS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY NGS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIBRARY PREPARATION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGET ENRICHMENT KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGET ENRICHMENT KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGET ENRICHMENT KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BIOINFORMATICS & DATA ANALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL REPORTING & INTERPRETATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL REPORTING & INTERPRETATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL REPORTING & INTERPRETATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLOGY NGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLOGY NGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLOGY NGS MARKET SIZE, BY OVARIAN CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLOGY NGS MARKET SIZE, BY OVARIAN CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGETED SEQUENCING & RESEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGETED SEQUENCING & RESEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TARGETED SEQUENCING & RESEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FRESH FROZEN TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FRESH FROZEN TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY NGS MARKET SIZE, BY FRESH FROZEN TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRE-SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRE-SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRE-SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DATA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMOR PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMOR PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SOLID TUMOR PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCY PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCY PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCY PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GERMLINE CANCER PREDISPOSITION TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GERMLINE CANCER PREDISPOSITION TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GERMLINE CANCER PREDISPOSITION TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLOGY NGS MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TUMOR HETEROGENEITY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TUMOR HETEROGENEITY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TUMOR HETEROGENEITY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESISTANCE MECHANISM STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESISTANCE MECHANISM STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RESISTANCE MECHANISM STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DRUG DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ONCOLOGY NGS MARKET SIZE, BY DRUG DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ONCOLOGY NGS MARKET SIZE, BY EARLY CANCER DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ONCOLOGY NGS MARKET SIZE, BY EARLY CANCER DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ONCOLOGY NGS MARKET SIZE, BY EARLY CANCER DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TREATMENT RESPONSE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TREATMENT RESPONSE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TREATMENT RESPONSE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RECURRENCE SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RECURRENCE SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONCOLOGY NGS MARKET SIZE, BY RECURRENCE SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ONCOLOGY NGS MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PATHOLOGY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. AFRICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 304. AFRICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 305. AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 306. AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. AFRICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 326. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE,